Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference
11:26am, Thursday, 21'st Nov 2024
Merck & Co., Inc. (NYSE:MRK ) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
08:15am, Thursday, 21'st Nov 2024
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across mu
Merck Announces First-Quarter 2025 Dividend
12:22pm, Tuesday, 19'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
11:28am, Tuesday, 19'th Nov 2024
In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Mark
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
10:49am, Tuesday, 19'th Nov 2024
The company has been preparing for the 2028 expiration of its patents protecting Keytruda.
Injectable version of cancer drug Keytruda works as well as current IV form: Merck
08:11am, Tuesday, 19'th Nov 2024
CNBC's Angelica Peebles reports on news from Merck.
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
07:54am, Tuesday, 19'th Nov 2024
The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.
Merck says Keytruda injection on par with approved IV version in trial
06:49am, Tuesday, 19'th Nov 2024
Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
06:45am, Tuesday, 19'th Nov 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 tri
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
11:35am, Monday, 18'th Nov 2024
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November
02:23am, Monday, 18'th Nov 2024
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases i
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
10:03pm, Friday, 15'th Nov 2024
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
03:40pm, Friday, 15'th Nov 2024
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
